Clinical Trials Logo
  1. Home
  2. Invasive Candidiasis
  3. NCT03906916

Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin — EPICA1  

Invasive Candidiasis Clinical Trial

Official title:
Multicenter Study to Compare Two Diagnostic Tests (1,3-β-D-glucan vs Blood Culture) in Critically Ill Patients With Suspected Invasive CAndidiasis Hospitalized in Internal Medicine Wards and Who Are Currently Timely Treated With Echinocandin (Micafungin)

Clinical Trial Summary

EPICA-1 is a multicenter, open label, interventional study which will involve about 30 Internal Medicine Units throughout Italy, enrolling globally at least 100 hospitalised patients with suspicion of invasive candidiasis. These patients will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test: this will allow collection of information on patients outcome. At the same time, patients will be also evaluated by means of blood culture, so that comparison will be possible between the two diagnostic tests (primary end-point of the study).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03906916
Study type Interventional
Source Fadoi Foundation, Italy
Contact
Status Terminated
Phase Phase 4
Start date July 18, 2018
Completion date February 1, 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05763251 - Comparison of Uncomplicated Candidemia Therapy Duration in Children N/A
Recruiting NCT01438216 - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients N/A
Terminated NCT01213823 - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins Phase 4
Completed NCT02491151 - Variability of Fluconazole Concentration in Critically Ill Patients N/A
Completed NCT01716988 - Pharmacokinetics of Micafungin in Critically Ill Patients N/A
Completed NCT00607763 - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00608335 - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug Phase 1
Completed NCT00786903 - Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen? N/A
Completed NCT00670657 - CRITIC - Treatment of Candidemia and Invasive Candidiasis Phase 4
Recruiting NCT04368559 - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Phase 3
Not yet recruiting NCT05707832 - A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive Aspergillus Phase 3
Recruiting NCT03538912 - Early Discontinuation of Empirical Antifungal Therapy and Biomarkers N/A
Completed NCT02801682 - NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis
Completed NCT02164890 - Pharmacokinetics of Micafungin in Patients of Intensive Care Units Phase 4
Completed NCT02841501 - Genetic Susceptibility Factors for Candidemia.
Completed NCT01047267 - Pharmacokinetics of Anidulafungin on Intensive Care Unit (ICU) N/A
Completed NCT00672841 - β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients N/A
Completed NCT02734862 - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Phase 2
Completed NCT01773876 - Empirical Antifungal Treatment in ICUS Phase 3
Completed NCT00689338 - Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Phase 3